PRTG Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	62 925.00
Average Volume	98 359.00
Market Cap	4.75M
EPS	$0 ( 2024-03-06 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.00600 (2.50%)

Volume Correlation

Long: 0.21 (neutral)

Short: -0.18 (neutral)

Signal:(45.509) Neutral

Portage Biotech Inc. Correlation

10 Most Positive Correlations
CSSEP	0.889
CZNC	0.886
AROW	0.874
FCBC	0.866
CMLS	0.862
IRBT	0.862
VGFC	0.861
BCBP	0.86
BWB	0.858
AFYA	0.857

10 Most Negative Correlations
CIIGU	-0.899
NVDA	-0.889
MCFT	-0.884
AMTBB	-0.882
TZPSU	-0.881
SVFA	-0.879
OFLX	-0.878
TZPS	-0.877
MPWR	-0.876
MCAA	-0.875

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Portage Biotech Inc. Correlation - Currency/Commodity

0.74
( moderate )

0.71
( moderate )

0.00
( neutral )

0.30
( neutral )

Portage Biotech Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1 000.00 (0.00 %)
EPS:	$-6.49

FY	2023
Revenue:	$0
Gross Profit:	$-1 000.00 (0.00 %)
EPS:	$-6.49

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.470

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.350

Financial Reports:

No articles found.

Portage Biotech Inc.

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.